PT  - JOURNAL ARTICLE
AU  - Tirona, Rommel G.
AU  - Kassam, Zahra
AU  - Strapp, Ruth
AU  - Ramu, Mala
AU  - Zhu, Catherine
AU  - Liu, Melissa
AU  - Schwarz, Ute I.
AU  - Kim, Richard B.
AU  - Al-Judaibi, Bandar
AU  - Beaton, Melanie D.
TI  - Apixaban and Rosuvas­­tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease
AID  - 10.1124/dmd.117.079624
DP  - 2018 May 01
TA  - Drug Metabolism and Disposition
PG  - 485--492
VI  - 46
IP  - 5
4099  - http://dmd.aspetjournals.org/content/46/5/485.short
4100  - http://dmd.aspetjournals.org/content/46/5/485.full
SO  - Drug Metab Dispos2018 May 01; 46
AB  - There is little known about the impact of nonalcoholic fatty liver disease (NAFLD) on drug metabolism and transport. We examined the pharmacokinetics of oral apixaban (2.5 mg) and rosuvastatin (5 mg) when administered simultaneously in subjects with magnetic resonance imaging–confirmed NAFLD (N = 22) and healthy control subjects (N = 12). The area under the concentration-time curve to the last sampling time (AUC0–12) values for apixaban were not different between control and NAFLD subjects (671 and 545 ng/ml × hour, respectively; P = 0.15). Similarly, the AUC0–12 values for rosuvastatin did not differ between the control and NAFLD groups (25.4 and 20.1 ng/ml × hour, respectively; P = 0.28). Furthermore, hepatic fibrosis in NAFLD subjects was not associated with differences in apixaban or rosuvastatin pharmacokinetics. Decreased systemic exposures for both apixaban and rosuvastatin were associated with increased body weight (P < 0.001 and P < 0.05, respectively). In multivariable linear regression analyses, only participant weight but not NAFLD, age, or SLCO1B1/ABCG2/CYP3A5 genotypes, was associated with apixaban and rosuvastatin AUC0–12 (P < 0.001 and P = 0.06, respectively). NAFLD does not appear to affect the pharmacokinetics of apixaban or rosuvastatin.